Andrew R. Thompsett

Publications (2)22.46 Total impact

• Chapter: DNA Fusion Vaccines Against B-Cell Tumors

  Delin Zhu, Myfanwy B. Spellerberg, Catherine A. King, Jason Rice, Andrew R. Thompsett, Freda K. Stevenson
  [show abstract] [hide abstract]
  ABSTRACT: The ability of naked DNA to induce immune responses against encoded antigen has been clearly demonstrated for infectious diseases (1). In many cases, the induced immunity is able to protect against infection, and can approach the efficacy of exogenous antigen (2).
  01/2008: pages 405-423;
• Article: DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma

  Catherine A. King, Myfanwy B. Spellerberg, Delin Zhu, Jason Rice, Surinder S. Sahota, Andrew R. Thompsett, Terry J. Hamblin, Jiri Radl, Freda K. Stevenson
  [show abstract] [hide abstract]
  ABSTRACT: Vaccination with idiotypic protein protects against B-cell lymphoma, mainly through anti-idiotypic antibody. For use in patients, DNA vaccines containing single-chain Fv derived from tumor provide a convenient alternative vaccine delivery system. However, single-chain Fv sequence alone induces low anti-idiotypic response and poor protection against lymphoma. Fusion of the gene encoding fragment C of tetanus toxin to single-chain Fv substantially promotes the anti-idiotypic response and induces strong protection against B-cell lymphoma. The same fusion design also induces protective immunity against a surface Ig-negative myeloma. These findings indicate that fusion to a pathogen sequence allows a tumor antigen to engage diverse immune mechanisms that suppress growth. This fusion design has the added advantage of overcoming potential tolerance to tumor that may exist in patients.
  Nature Medicine 10/1998; 4(11):1281-1286. · 22.46 Impact Factor